{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T12:43:43Z","timestamp":1777898623385,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd015236","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000}}],"reference-count":84,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015236.pub2","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:28:04Z","timestamp":1695810484000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prebiotics for people with cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Neil C","family":"Williams","sequence":"additional","affiliation":[{"name":"Exercise and Health Research Group, Sport Health and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology.; Nottingham Trent University; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Jayaratnasingam","sequence":"additional","affiliation":[{"name":"Exercise and Health Research Group, Sport Health and Performance Enhancement (SHAPE) Research Centre, School of Science and Technology.; Nottingham Trent University; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P","family":"Prayle","sequence":"additional","affiliation":[{"name":"Nottingham Cystic Fibrosis and Chidlren's Respiratory Research Centre; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J","family":"Nevitt","sequence":"additional","affiliation":[{"name":"Department of Health Data Science; University of Liverpool; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG); School of Medicine, University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD015236.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41430-017-0043-4","article-title":"Effect of synbiotic supplementation in children and adolescents with cystic fibrosis: a randomized controlled clinical trial","volume":"72","author":"Freitas","year":"2018","journal-title":"European Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0002|cit2","unstructured":"A double-blind, randomized, placebo-controlled, cross-over study to evaluate the safety, tolerability and preliminary efficacy of alginate oligosaccharide (OligoG) administered for 28 days in subjects with Cystic Fibrosis chronically colonised with Pseudomonas aeruginosa trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-023090-19-GB"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0003|cit3","unstructured":"A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE"},{"issue":"5","key":"10.1002\/14651858.CD015236.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jcf.2022.01.003","article-title":"Evaluating the alginate oligosaccharide (OligoG) as a therapy for Burkholderia cepacia complex cystic fibrosis lung infection","volume":"21","author":"Fischer","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0005|cit5","unstructured":"A study of OligoG in cystic fibrosis subjects with burkholderia Spp. infection clinicaltrials.gov\/ct2\/show\/study\/NCT02453789"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0006|cit6","unstructured":"Effect of synbiotic supplementation in comparison with placebo on anthropometric indeices, quality of life and clinical outcome in children with cystic fibrosis en.irct.ir\/trial\/25032"},{"issue":"6","key":"10.1002\/14651858.CD015236.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s004310051119","article-title":"Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance","volume":"158","author":"Kentrup","year":"1999","journal-title":"European Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD015236.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/andr.12336","article-title":"The association of a probiotic with a prebiotic (Flortec, Bracco) to improve the quality\/quantity of spermatozoa in infertile patients with idiopathic oligoasthenoteratospermia: a pilot study","volume":"5","author":"Maretti","year":"2017","journal-title":"Andrology"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0009|cit9","unstructured":"Safety and efficacy of inhaled OligoG CF-5\/20 for the treatment cystic cibrosis clinicaltrials.gov\/ct2\/show\/study\/NCT00970346"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0010|cit10","unstructured":"A cross-over study of OligoG in subjects with cystic fibrosis. Fibrosis (OligoG) clinicaltrials.gov\/ct2\/show\/study\/NCT01465529"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0011|cit11","unstructured":"Effect of Lactobacillus Reuteri in cystic fibrosis clinicaltrials.gov\/ct2\/show\/study\/NCT01737983"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0012|cit12","unstructured":"A phase IIb study of OligoG in subjects with cystic fibrosis (SMR-2984) clinicaltrials.gov\/ct2\/show\/study\/NCT02157922"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0013|cit13","unstructured":"A dose-finding study of inhaled OligoG vs placebo in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/study\/NCT03698448"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0014|cit14","unstructured":"A phase 2b randomised, placebo controlled study of OligoG in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/study\/NCT03822455"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0015|cit15","unstructured":"Vitamin D and prebiotics for intestinal health in cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT04118010"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jhn.12991","article-title":"Probiotic use in adults with cystic fibrosis is common and influenced by gastrointestinal health needs: a cross-sectional survey study","volume":"35","author":"Anderson","year":"2022","journal-title":"Journal of Human Nutrition and Dietetics"},{"issue":"16","key":"10.1002\/14651858.CD015236.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"e00274","DOI":"10.1128\/JB.00274-19","article-title":"Altered stool microbiota of infants with cystic fibrosis shows a reduction in genera associated with immune programming from birth","volume":"201","author":"Antosca","year":"2019","journal-title":"Journal of Bacteriology"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0019|cit19","first-page":"1","article-title":"The altered gut microbiota in adults with cystic fibrosis","volume":"17","author":"Burke","year":"2017","journal-title":"BMC Microbiology"},{"issue":"7","key":"10.1002\/14651858.CD015236.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.biopsych.2016.12.031","article-title":"Targeting the microbiota-gut-brain axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice","volume":"82","author":"Burokas","year":"2017","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0021|cit21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012949.pub2","article-title":"Probiotics for people with cystic fibrosis","author":"Coffey","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD015236.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0895-4356(88)90063-7","article-title":"A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto","volume":"41","author":"Corey","year":"1988","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1038\/cti.2016.17","article-title":"Regulation of immune cell function by short-chain fatty acids","volume":"5","author":"Corr\u00eaa-Oliveira","year":"2016","journal-title":"Clinical & Translational Immunology"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0024|cit24","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0025|cit25","unstructured":"Cystic Fibrosis Foundation Patient Registry 2020 Annual data report www.cff.org\/sites\/default\/files\/2021-10\/2019-Patient-Registry-Annual-Data-Report.pdf"},{"issue":"6","key":"10.1002\/14651858.CD015236.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"e0198457","DOI":"10.1371\/journal.pone.0198457","article-title":"Altered intestinal microbiota composition, antibiotic therapy and intestinal inflammation in children and adolescents with cystic fibrosis","volume":"13","author":"Freitas","year":"2018","journal-title":"PLOS One"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0027|cit27","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/MPG.0000000000000683","article-title":"Intestinal inflammation and impact on growth in children with cystic fibrosis","volume":"60","author":"Dhaliwal","year":"2015","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gtc.2016.09.007","article-title":"The microbiome-gut-brain axis in health and disease","volume":"46","author":"Dinan","year":"2017","journal-title":"Gastroenterology Clinics of North America"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ejcn.2009.120","article-title":"A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers' diarrhoea","volume":"64","author":"Drakoularakou","year":"2010","journal-title":"European Journal of Clinical Nutrition"},{"issue":"22","key":"10.1002\/14651858.CD015236.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1128\/AEM.05933-11","article-title":"Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings","volume":"77","author":"Duytschaever","year":"2011","journal-title":"Applied and Environmental Microbiology"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"Journal of Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD015236.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD015236.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/jn\/125.6.1401","article-title":"Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics","volume":"125","author":"Gibson","year":"1995","journal-title":"Journal of Nutrition"},{"issue":"S1","key":"10.1002\/14651858.CD015236.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1079\/BJN20041343","article-title":"Prebiotics and resistance to gastrointestinal infections","volume":"93","author":"Gibson","year":"2005","journal-title":"British Journal of Nutrition"},{"issue":"8","key":"10.1002\/14651858.CD015236.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3920\/BM2020.0062","article-title":"Clinical evaluation of the synbiotic Prodefen Plus\u00ae in the prevention of the antibiotic-associated diarrhoea in subjects requiring antibiotic treatment","volume":"11","author":"Guridi","year":"2020","journal-title":"Beneficial Microbes"},{"issue":"7414","key":"10.1002\/14651858.CD015236.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0040|cit40","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0041|cit41","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0042|cit42","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"8","key":"10.1002\/14651858.CD015236.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Hill","year":"2014","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"10","key":"10.1002\/14651858.CD015236.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1210\/jc.2019-00481","article-title":"Effect of prebiotic on microbiota, intestinal permeability, and glycemic control in children with type 1 diabetes","volume":"104","author":"Ho","year":"2019","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jpeds.2015.02.049","article-title":"Associations between gut microbial colonization in early life and respiratory outcomes in cystic fibrosis","volume":"167","author":"Hoen","year":"2015","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD015236.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3945\/ajcn.110.004119","article-title":"Growth and pulmonary outcomes during the first 2 y of life of breastfed and formula-fed infants diagnosed with cystic fibrosis through the Wisconsin Routine Newborn Screening Program","volume":"93","author":"Jadin","year":"2011","journal-title":"American Journal of Clinical Nutrition"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40271-019-00361-2","article-title":"Validity and reliability of a novel multimodal questionnaire for the assessment of abdominal symptoms in people with cystic fibrosis (CFAbd-Score)","volume":"12","author":"Jaudszus","year":"2019","journal-title":"Patient"},{"issue":"7","key":"10.1002\/14651858.CD015236.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1017\/S0007114513003607","article-title":"Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials","volume":"111","author":"Kellow","year":"2014","journal-title":"British Journal of Nutrition"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1038\/s41598-022-10328-3","article-title":"Alterations of mucosa-attached microbiome and epithelial cell numbers in the cystic fibrosis small intestine with implications for intestinal disease","volume":"12","author":"Kelly","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"948367","DOI":"10.1155\/2012\/948367","article-title":"Update of faecal markers of inflammation in children with cystic fibrosis","volume":"2012","author":"Lee","year":"2012","journal-title":"Mediators of Inflammation"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.clnu.2014.04.004","article-title":"The clinical significance of the gut microbiotain cystic fibrosis and the potential for dietary therapies","volume":"33","author":"Li","year":"2014","journal-title":"Clinical Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD015236.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tifs.2011.08.011","article-title":"Prebiotics for prevention of gut infections","volume":"23","author":"Licht","year":"2012","journal-title":"Trends in Food Science & Technology"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"e00251","DOI":"10.1128\/mBio.00251-12","article-title":"Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures","volume":"3","author":"Madan","year":"2012","journal-title":"MBio"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"877118","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis \u2013 early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ifset.2013.10.016","article-title":"Gut microbiota modulation and implications for host health: dietary strategies to influence the gut\u2013brain axis","volume":"22","author":"Marques","year":"2014","journal-title":"Innovative Food Science & Emerging Technologies"},{"issue":"2","key":"10.1002\/14651858.CD015236.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1513\/AnnalsATS.201503-133AW","article-title":"The gut-lung axis in respiratory disease","volume":"12","author":"Marsland","year":"2015","journal-title":"Annals of the American Thoracic Society"},{"issue":"9719","key":"10.1002\/14651858.CD015236.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0140-6736(09)62161-9","article-title":"Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis","volume":"375","author":"McCormick","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD015236.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.jand.2020.03.016","article-title":"Dietary macronutrient distribution and nutrition outcomes in persons with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"McDonald","year":"2021","journal-title":"Journal of the Academy of Nutrition and Dietetics"},{"issue":"19","key":"10.1002\/14651858.CD015236.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015236.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3945\/jn.115.220749","article-title":"Human milk oligosaccharides and synthetic galactosyloligosaccharides contain 3'-, 4-, and 6'-galactosyllactose and attenuate inflammation in human T84, NCM-460, and H4 cells and intestinal tissue ex vivo","volume":"146","author":"Newburg","year":"2016","journal-title":"Journal of Nutrition"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep24857","article-title":"Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis","volume":"6","author":"Nielsen","year":"2016","journal-title":"Scientific Reports"},{"issue":"10","key":"10.1002\/14651858.CD015236.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1007\/s10620-015-3842-2","article-title":"Fecal human \u03b2-defensin 2 in children with cystic fibrosis: is there a diminished intestinal innate immune response?","volume":"60","author":"Ooi","year":"2015","journal-title":"Digestive Diseases and Sciences"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"17834","DOI":"10.1038\/s41598-018-36364-6","article-title":"Impact of CFTR modulation with ivacaftor on gut microbiota and intestinal inflammation","volume":"8","author":"Ooi","year":"2018","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1002\/14651858.CD015236.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"18","key":"10.1002\/14651858.CD015236.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0066|cit66","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"10","key":"10.1002\/14651858.CD015236.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41575-019-0173-3","article-title":"Probiotics and prebiotics in intestinal health and disease: from biology to the clinic","volume":"16","author":"Sanders","year":"2019","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/978-3-030-80068-0_53","volume-title":"Textbook of Pediatric Gastroenterology, Hepatology and Nutrition","author":"Savino","year":"2022"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0069|cit69","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/jam.14424","article-title":"Developments in understanding and applying prebiotics in research and practice \u2013 an ISAPP conference paper","volume":"128","author":"Scott","year":"2020","journal-title":"Journal of Applied Microbiology"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jff.2012.07.002","article-title":"Low molecular weight fractions of BiMuno\u00ae exert immunostimulatory properties in murine macrophages","volume":"4","author":"Searle","year":"2012","journal-title":"Journal of Functional Foods"},{"issue":"3","key":"10.1002\/14651858.CD015236.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1152\/physrev.00045.2009","article-title":"Gut microbiota in health and disease","volume":"90","author":"Sekirov","year":"2010","journal-title":"Physiological Reviews"},{"issue":"5","key":"10.1002\/14651858.CD015236.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2036.2008.03911.x","article-title":"Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome","volume":"29","author":"Silk","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015236.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"e000614","DOI":"10.1136\/bmjresp-2020-000614","article-title":"How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey","volume":"7","author":"Smith","year":"2020","journal-title":"BMJ Open Respiratory Research"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1542\/peds.34.1.72","article-title":"Fecal retention in children with cystic fibrosis: report of three cases","volume":"34","author":"Snyder","year":"1964","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"Journal of the American Dietetic Association"},{"key":"10.1002\/14651858.CD015236.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"Suppl 41","key":"10.1002\/14651858.CD015236.pub2-BIB0078|cit78","first-page":"407","article-title":"Probiotic use and antibiotic associated gastrointestinal symptoms in pediatric patients with cystic fibrosis","volume":"50","author":"Sullivan","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD015236.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jcf.2018.03.011","article-title":"Dietary intake of energy-dense, nutrient-poor and nutrient-dense food sources in children with cystic fibrosis","volume":"17","author":"Sutherland","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"issue":"40","key":"10.1002\/14651858.CD015236.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"E5934","DOI":"10.1073\/pnas.1612559113","article-title":"High-fat diet modifies the PPAR-\u03b3 pathway leading to disruption of microbial and physiological ecosystem in murine small intestine","volume":"113","author":"Tomas","year":"2016","journal-title":"National Academy of Sciences of the USA"},{"issue":"3","key":"10.1002\/14651858.CD015236.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clinical Nutrition"},{"issue":"12","key":"10.1002\/14651858.CD015236.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"e0208171","DOI":"10.1371\/journal.pone.0208171","article-title":"Gut microbiota signatures in cystic fibrosis: loss of host CFTR function drives the microbiota enterophenotype","volume":"13","author":"Vernocchi","year":"2018","journal-title":"PLOS ONE"},{"issue":"4","key":"10.1002\/14651858.CD015236.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00223-017-0339-3","article-title":"Prebiotics, bone and mineral metabolism","volume":"102","author":"Whisner","year":"2018","journal-title":"Calcified Tissue International"},{"issue":"12","key":"10.1002\/14651858.CD015236.pub2-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015236","article-title":"Prebiotics for people with cystic fibrosis","author":"Williams","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T07:57:33Z","timestamp":1721116653000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015236.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":84,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015236.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]}}}